January 07, 2022
In the news release, Trulieve Announces Grand Opening of its Affiliate's (Chamounix Ventures, LLC) Philadelphia Dispensary, issued 07-Jan-2022 by Trulieve Cannabis Corp. over PR Newswire, we are advised by the company that the headline and first paragraph, first sentence, should read " Affiliate's (Harvest of Southeast, PA, LLC) Philadelphia Dispensary" and "through its affiliate, Harvest of Southeast, PA, LLC" rather than "Affiliate's (Chamounix Ventures, LLC) Philadelphia Dispensary" and "through its affiliate, Chamounix Ventures, LLC" as originally issued inadvertently. The complete, corrected release follows:
Trulieve Announces Grand Opening of its Affiliate's (Harvest of Southeast, PA, LLC) Philadelphia Dispensary
Medical marijuana dispensary opens Saturday, January 8
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new Trulieve-branded medical marijuana dispensary through its affiliate, Harvest of Southeast, PA, LLC. The dispensary at 1222 Arch St. is in the Center City section of Philadelphia . This location becomes the Company's 160th owned, operated or affiliated dispensary nationwide.
Located in the heart of Philadelphia , between City Hall and Reading Terminal Market, the dispensary will be open Monday – Saturday from 9am – 8pm and on Sunday from 10am – 6pm . Patients can choose from Trulieve's selection of premium whole flower products, including TruFlower and Cultivar Collection, as well as a wide range of vapes, tinctures, topicals and ingestibles.
"We are proud to begin the New Year by demonstrating our ongoing commitment to serving Pennsylvania's patient community through high quality and reliable medical marijuana products," said Kim Rivers , CEO of Trulieve. "We look forward to welcoming patients and strengthening community connections in this cornerstone market."
Additional Trulieve-affiliated dispensaries in Pennsylvania are located in Camp Hill , Cranberry Township , Devon , Harrisburg , Johnstown , King of Prussia , Pittsburgh , Reading , Scranton , Washington , Whitehall , York and Zelienople .
To find a location or to learn how to become a registered patient, visit Trulieve.com , follow us on Instagram at trulieve_pa or connect with Trulieve PA on Facebook.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey , Director of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com
MATTIO Communications
Trulieve@Mattio.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-grand-opening-of-its-affiliates-chamounix-ventures-llc-philadelphia-dispensary-301456254.html
SOURCE Trulieve Cannabis Corp.

News Provided by PR Newswire via QuoteMedia
TCNNF,TRUL:CNX
The Conversation (0)
19 September
Cannabis Crossroads: Record US Demand Meets Federal Gridlock
The US cannabis industry is at a turning point. State-level legalization and retail growth continue to accelerate, but federal policy remains stalled, leaving businesses navigating both opportunity and uncertainty. Record consumer demand is driving sales, yet outdated regulations, restrictive... Keep Reading...
22 July
10 Biggest Cannabis Stocks in the US and Canada in 2025
After initial optimism for rescheduling in the US, the cannabis market has faced challenges in 2025. Despite signs of support from US President Donald Trump and members of his administration, regulatory uncertainty persists in the US. Companies are shifting focus to match changes in consumer... Keep Reading...
17 July
Cannabis Market Update: H1 2025 in Review
The first half of 2025 played out differently than many cannabis market participants expected. Heading into the year, there was optimism that rescheduling in the US would reduce or eliminate challenges, but the industry continued to grapple with persistent federal regulatory uncertainty,... Keep Reading...
25 June
Thailand Reverses Course on Cannabis, Moves to Recriminalize Amid Political Fallout
Thailand’s groundbreaking experiment with cannabis decriminalization is rapidly unraveling, with the government formally moving to reclassify the plant as a narcotic and ban recreational sales.The decision has sent shockwaves through an industry once projected to be worth over US$1 billion.The... Keep Reading...
09 May
A State-by-State Guide to Cannabis in Australia
Australia federally legalised medicinal cannabis in 2016, and Australia's cannabis market has seen major growth since then.Medical cannabis approvals were up by 120 percent in the first half of 2023 compared to the same period in 2022. Statista forecasts that Australian cannabis revenue will... Keep Reading...
01 May
New Cannabis Consumption Trends, Regulatory Shifts Seen Driving Market in 2025
Understanding trends in the cannabis industry is paramount for investors eyeing a market with steady growth potential, but the landscape is complex as products and regulations continue to evolve. Consumption habits are changing as edibles, vaping and THC beverages gain traction, especially among... Keep Reading...
Latest News
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00